Jean-Emmanuel Bibault

Dr. Jean-Emmanuel Bibault

Radiation Oncology Department, Hôpital Européen Georges Pompidou, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Cancer Letters
Verified
Journal Article
Closed access
Jean-Emmanuel BibaultJean-Emmanuel Bibault
Jean-Emmanuel Bibault
PGPhilippe Giraud
Philippe Giraud
ABAnita Burgun
Anita Burgun

2 May 2019 in JMIR Cancer
Verified
Journal Article
Open access
BCBenjamin Chaix
Benjamin Chaix
Jean-Emmanuel BibaultJean-Emmanuel Bibault
Jean-Emmanuel Bibault
APArthur Pienkowski
Arthur Pienkowski
GDGuillaume Delamon
Guillaume Delamon
AGArthur Guillemassé
Arthur Guillemassé
BBBenoît Brouard
Benoît Brouard
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Chatbots are softwares that interact with users by simulating a human conversation through text or voice via smartphones or computers. They could be a solution to follow-up with patients during their disease while saving time for healthcare providers. Objective: To evaluate 1 year of conversations between patients with breast cancer and a chatbot. Methods: Wefight Inc. designed a chatbot (Vik) to empower patients with breast cancer and their relatives. Vik answers the fears and concerns of patients with breast cancer using personalized insights through text messages. We conducted a prospective study by analyzing the users'/patients data, their usage duration, their interest in the various educational contents proposed and their level of interactivity. Patients were women with breast cancer or under remission. Results: 4737 patients were included. Results show that an average of 132,970 messages exchanged per month was observed between patients and the chatbot Vik. Thus, we calculated the average medication adherence rate over 4 weeks by using a prescription reminder function and we showed that the more the patients use it, the more adherent they are. Patients regularly leave positive comments and recommend Vik to their friends. The overall satisfaction is 94%. When we ask them what Vik means to them and what Vik brings them, 88% say that Vik provides them with support and helps them to track their treatment effectively. Conclusions: We show that it is possible to obtain support through a chatbot. Thus, we showed that the chatbot Vik improves the medication adherence rate of patients with breast cancer.

27 November 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Jean-Emmanuel BibaultJean-Emmanuel Bibault
Jean-Emmanuel Bibault
BCBenjamin Chaix
Benjamin Chaix
AGArthur Guillemassé
Arthur Guillemassé
SCSophie Cousin
Sophie Cousin
AEAlexandre Escande
Alexandre Escande
BBBenoît Brouard
Benoît Brouard
Background: The data regarding the use of conversational agents in oncology are scarce. Objective: The aim of this study was to verify whether an artificial conversational agent was able to provide answers to patients with breast cancer with a level of satisfaction similar to the answers given by a group of physicians. Methods: This study is a blind, noninferiority randomized controlled trial that compared the information given by the chatbot, Vik, with that given by a multidisciplinary group of physicians to patients with breast cancer. Patients were women with breast cancer in treatment or in remission. The European Organisation for Research and Treatment of Cancer Quality of Life Group information questionnaire (EORTC QLQ-INFO25) was adapted and used to compare the quality of the information provided to patients by the physician or the chatbot. The primary outcome was to show that the answers given by the Vik chatbot to common questions asked by patients with breast cancer about their therapy management are at least as satisfying as answers given by a multidisciplinary medical committee by comparing the success rate in each group (defined by a score above 3). The secondary objective was to compare the average scores obtained by the chatbot and physicians for each INFO25 item. Results: A total of 142 patients were included and randomized into two groups of 71. They were all female with a mean age of 42 years (SD 19). The success rates (as defined by a score >3) was 69% (49/71) in the chatbot group versus 64% (46/71) in the physicians group. The binomial test showed the noninferiority (P<.001) of the chatbot’s answers. Conclusions: This is the first study that assessed an artificial conversational agent used to inform patients with cancer. The EORTC INFO25 scores from the chatbot were found to be noninferior to the scores of the physicians. Artificial conversational agents may save patients with minor health concerns from a visit to the doctor. This could allow clinicians to spend more time to treat patients who need a consultation the most. Trial Registration: Clinicaltrials.gov NCT03556813, https://tinyurl.com/rgtlehq

22 August 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Jean-Emmanuel BibaultJean-Emmanuel Bibault
Jean-Emmanuel Bibault
PGPhilippe Giraud
Philippe Giraud
MHMartin Housset
Martin Housset
CDCatherine Durdux
Catherine Durdux
Julien TaiebJulien Taieb
Julien Taieb
ABAnita Burgun
Anita Burgun
Treatment of locally advanced rectal cancer involves chemoradiation, followed by total mesorectum excision. Complete response after chemoradiation is an accurate surrogate for long-term local control. Predicting complete response from pre-treatment features could represent a major step towards conservative treatment. Patients with a T2-4 N0-1 rectal adenocarcinoma treated between June 2010 and October 2016 with neo-adjuvant chemoradiation from three academic institutions were included. All clinical and treatment data was integrated in our clinical data warehouse, from which we extracted the features. Radiomics features were extracted from the tumor volume from the treatment planning CT Scan. A Deep Neural Network (DNN) was created to predict complete response, as a methodological proof-of-principle. The results were compared to a baseline Linear Regression model using only the TNM stage as a predictor and a second model created with Support Vector Machine on the same features used in the DNN. Ninety-five patients were included in the final analysis. There were 49 males (52%) and 46 females (48%). Median tumour size was 48 mm (15–130). Twenty-two patients (23%) had pathologic complete response after chemoradiation. One thousand six hundred eighty-three radiomics features were extracted. The DNN predicted complete response with an 80% accuracy, which was better than the Linear Regression model (69.5%) and the SVM model (71.58%). Our model correctly predicted complete response after neo-adjuvant rectal chemoradiotherapy in 80% of the patients of this multicenter cohort. Our results may help to identify patients who would benefit from a conservative treatment, rather than a radical resection.

1 October 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LBLuca Boldrini
Luca Boldrini
Jean-Emmanuel BibaultJean-Emmanuel Bibault
Jean-Emmanuel Bibault
CMCarlotta Masciocchi
Carlotta Masciocchi
YSYanting Shen
Yanting Shen
MBMartin-Immanuel Bittner
Martin-Immanuel Bittner
Introduction: Deep Learning (DL) is a machine learning technique that uses deep neural networks to create a model. The application areas of deep learning in radiation oncology include image segmentation and detection, image phenotyping, and radiomic signature discovery, clinical outcome prediction, image dose quantification, dose-response modeling, radiation adaptation, and image generation. In this review, we explain the methods used in DL and perform a literature review using the Medline database to identify studies using deep learning in radiation oncology. The search was conducted in April 2018, and identified studies published between 1997 and 2018, strongly skewed toward 2015 and later. Methods: A literature review was performed using PubMed/Medline in order to identify important recent publications to be synthesized into a review of the current status of Deep Learning in radiation oncology, directed at a clinically-oriented reader. The search strategy included the search terms “radiotherapy” and “deep learning.” In addition, reference lists of selected articles were hand searched for further potential hits of relevance to this review. The search was conducted in April 2018, and identified studies published between 1997 and 2018, strongly skewed toward 2015 and later. Results: Studies using DL for image segmentation were identified in Brain (n = 2), Head and Neck (n = 3), Lung (n = 6), Abdominal (n = 2), and Pelvic (n = 6) cancers. Use of Deep Learning has also been reported for outcome prediction, such as toxicity modeling (n = 3), treatment response and survival (n = 2), or treatment planning (n = 5). Conclusion: Over the past few years, there has been a significant number of studies assessing the performance of DL techniques in radiation oncology. They demonstrate how DL-based systems can aid clinicians in their daily work, be it by reducing the time required for or the variability in segmentation, or by helping to predict treatment outcomes and toxicities. It still remains to be seen when these techniques will be employed in routine clinical practice.

11 October 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Jean-Emmanuel BibaultJean-Emmanuel Bibault
Jean-Emmanuel Bibault
SDSylvain Dewas
Sylvain Dewas
CVClaire Vautravers-Dewas
Claire Vautravers-Dewas
AHAntoine Hollebecque
Antoine Hollebecque
HJHajer Jarraya
Hajer Jarraya
XMXavier MIRABEL
Xavier MIRABEL
Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) has been evaluated in several recent studies. The CyberKnife® is an SBRT system that allows for real-time tracking of the tumor. The purpose of this study was to evaluate the prognostic factors for local control and overall survival following this treatment. 75 patients with 96 liver-confined HCC were treated with SBRT at the Oscar Lambret Comprehensive Cancer Center. Fiducials were implanted in the liver before treatment and were used as markers to track the lesion’s movement. Treatment response was scored according to RECIST v1.1. Local control and overall survival were calculated using the Kaplan and Meier method. A stepwise multivariate analysis (Cox regression) of prognostic factors was performed for local control and overall survival. There were 67 patients with Child-Turcotte-Pugh (CTP) Class A and eight patients with CTP Class B. Treatment was administered in three sessions. A total dose of 40–45 Gy to the 80% isodose line was delivered. The median follow-up was 10 months (range, 3–49 months). The local control rate was 89.8% at 1 and 2 years. Overall survival was 78.5% and 50.4% at 1 and 2 years, respectively. Toxicity mainly consisted of grade 1 and grade 2 events. Higher alpha-fetoprotein (aFP) levels were associated with less favorable local control (HR=1.001; 95% CI [1.000, 1.002]; p=0.0063). A higher dose was associated with better local control (HR=0.866; 95% CI [0.753, 0.996]; p=0.0441). A Child-Pugh score higher than 5 was associated with worse overall survival (HR= 3.413; 95% CI [1.235, 9.435]; p=0.018). SBRT affords good local tumor control and higher overall survival rates than other historical controls (best supportive care or sorafenib). High aFP levels were associated with lesser local control, but a higher treatment dose improved local control.